Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
OMED's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: No Debt )
OMED' s 10-Year Cash to Debt Range
Min: 326.31   Max: No Debt
Current: No Debt

Equity to Asset 0.33
OMED's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: 0.33 )
OMED' s 10-Year Equity to Asset Range
Min: -2.45   Max: 0.7
Current: 0.33

-2.45
0.7
Interest Coverage No Debt
OMED's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: No Debt )
OMED' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 1.55
M-Score: -3.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -80.27
OMED's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: -80.27 )
OMED' s 10-Year Operating margin (%) Range
Min: -161.06   Max: -48.52
Current: -80.27

-161.06
-48.52
Net-margin (%) -84.87
OMED's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: -84.87 )
OMED' s 10-Year Net-margin (%) Range
Min: -152.47   Max: -47.87
Current: -84.87

-152.47
-47.87
ROE (%) -73.04
OMED's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: -73.04 )
OMED' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -73.04

ROA (%) -16.48
OMED's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: -16.48 )
OMED' s 10-Year ROA (%) Range
Min: -28.05   Max: -12.61
Current: -16.48

-28.05
-12.61
ROC (Joel Greenblatt) (%) -728.10
OMED's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: -728.10 )
OMED' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -495.29   Max: -385.14
Current: -728.1

-495.29
-385.14
» OMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

OMED Guru Trades in Q3 2013

Steven Cohen 38,893 sh (New)
PRIMECAP Management 244,700 sh (New)
» More
Q4 2013

OMED Guru Trades in Q4 2013

PRIMECAP Management 340,700 sh (+39.23%)
Steven Cohen Sold Out
» More
Q1 2014

OMED Guru Trades in Q1 2014

PRIMECAP Management 340,700 sh (unchged)
» More
Q2 2014

OMED Guru Trades in Q2 2014

Jim Simons 59,200 sh (New)
PRIMECAP Management 266,400 sh (-21.81%)
» More
» Details

Insider Trades

Latest Guru Trades with OMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2014-06-30 Reduce -21.81%$21.21 - $32.59 $ 19.11-23%266400
PRIMECAP Management 2013-12-31 Add 39.23%$12.31 - $29.65 $ 19.115%340700
PRIMECAP Management 2013-09-30 New Buy$15.98 - $27.18 $ 19.113%244700
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.13
OMED's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: 6.13 )
OMED' s 10-Year P/B Range
Min: 3.52   Max: 9.74
Current: 6.13

3.52
9.74
P/S 11.72
OMED's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: 11.72 )
OMED' s 10-Year P/S Range
Min: 1.03   Max: 15.03
Current: 11.72

1.03
15.03
PFCF 5.38
OMED's PFCF is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: 5.38 )
OMED' s 10-Year PFCF Range
Min: 4.83   Max: 49.97
Current: 5.38

4.83
49.97
EV-to-EBIT -8.76
OMED's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: -8.76 )
OMED' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -8.76

Current Ratio 5.34
OMED's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: 5.34 )
OMED' s 10-Year Current Ratio Range
Min: 1.89   Max: 5.88
Current: 5.34

1.89
5.88
Quick Ratio 5.34
OMED's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: 5.34 )
OMED' s 10-Year Quick Ratio Range
Min: 1.89   Max: 5.88
Current: 5.34

1.89
5.88

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.58
OMED's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: 7.58 )
OMED' s 10-Year Price/Net Cash Range
Min: 5.05   Max: 11.29
Current: 7.58

5.05
11.29
Price/Net Current Asset Value 7.58
OMED's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: 7.58 )
OMED' s 10-Year Price/Net Current Asset Value Range
Min: 4.64   Max: 11.29
Current: 7.58

4.64
11.29
Price/Tangible Book 6.12
OMED's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: 6.12 )
OMED' s 10-Year Price/Tangible Book Range
Min: 4.22   Max: 9.37
Current: 6.12

4.22
9.37
Price/Median PS Value 2.07
OMED's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OMED: 2.07 )
OMED' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 2.42
Current: 2.07

0.22
2.42

Business Description

Industry: »
Compare: » details
Traded in other countries:O0M.Germany
OncoMed Pharmaceuticals Inc was originally incorporated in July 2004. The Company is engaged in the development of monoclonal antibody drugs that target cancer stem cells, or CSCs. The Company has five product candidates in clinical development. The first candidate, demcizamab (OMP-21M18) has completed a single-agent Phase Ia safety and dose escalation trial and is currently in Phase Ib solid tumor combination therapy studies. The second candidate, anti-Notch 2/3 (OMP-59R5), is in combination therapy Phase Ib/II trials in pancreatic and small cell lung cancer. The third, fourth and fifth candidates, vantictumab (OMP-18R5), Fzd8-Fc (OMP-54F28) and anti-Notch1 (OMP-52M51), are in single-agent Phase I safety and dose escalation trials. The clinical trials for all five product candidates are ongoing, with the intent of gathering additional data required to proceed to later stage clinical trials and product approval. These product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK